Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro

被引:155
作者
Levine, S [1 ]
Hernandez, D [1 ]
Yamanaka, G [1 ]
Zhang, S [1 ]
Rose, R [1 ]
Weinheimer, S [1 ]
Colonno, RJ [1 ]
机构
[1] Bristol Myers Squibb Co, Pharmaceut Res Inst, Wallingford, CT 06492 USA
关键词
D O I
10.1128/AAC.46.8.2525-2532.2002
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Entecavir (ETV) is a potent and selective inhibitor of hepatitis B virus (HBV) replication in vitro and in vivo that is currently in clinical trials for the treatment of chronic HBV infections. A major limitation of the current HBV antiviral therapy, lamivudine (3TC), is the emergence of drug-resistant HBV in a majority of treated patients due to specific mutations in the nucleotide binding site of HBV DNA polymerase (HBV Pol). To determine the effects of 3TC resistance mutations on inhibition by ETV triphosphate (ETV-TP), a series of in vitro studies were performed. The inhibition of wild-type and 3TC-resistant HBV Pol by ETV-TP was measured using recombinant HBV nucleocapsids, and compared to that of 3TC-TP. These enzyme inhibition studies demonstrated that ETV-TP is a highly potent inhibitor of wild-type HBV Pol and is 100- to 300-fold more potent than 3TC-TP against 3TC-resistant HBV Pol. Cell culture assays were used to gauge the potential for antiviral cross-resistance of 3TC-resistant mutants to ETV. Results demonstrated that ETV inhibited the replication of 3TC-resistant HBV, but 20- to 30-fold higher concentrations were required. To gain further perspective regarding the potential therapeutic use of ETV, its phosphorylation was examined in hepatoma cells treated with extracellular concentrations representative of drug levels in plasma in ETV-treated patients. At these concentrations, intracellular ETV-TP accumulated to levels expected to inhibit the enzyme activity of both wild-type and 3TC-resistant HBV Pol. These findings are predictive of potent antiviral activity of ETV against both wild-type and 3TC-resistant HBV.
引用
收藏
页码:2525 / 2532
页数:8
相关论文
共 32 条
[1]   Identification and characterization of mutations in hepatitis B virus resistant to lamivudine [J].
Allen, MI ;
Deslauriers, M ;
Andrews, CW ;
Tipples, GA ;
Walters, KA ;
Tyrrell, DLJ ;
Brown, N ;
Condreay, LD .
HEPATOLOGY, 1998, 27 (06) :1670-1677
[2]   AMPLIFICATION OF EXPRESSION OF HEPATITIS-B SURFACE-ANTIGEN IN 3T3 CELLS COTRANSFECTED WITH A DOMINANT-ACTING GENE AND CLONED VIRAL-DNA [J].
CHRISTMAN, JK ;
GERBER, M ;
PRICE, PM ;
FLORDELLIS, C ;
EDELMAN, J ;
ACS, G .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1982, 79 (06) :1815-1819
[3]   Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection [J].
Colonno, RJ ;
Genovesi, EV ;
Medina, I ;
Lamb, L ;
Durham, SK ;
Huang, ML ;
Corey, L ;
Littlejohn, M ;
Locarnini, S ;
Tennant, BC ;
Rose, B ;
Clark, JM .
JOURNAL OF INFECTIOUS DISEASES, 2001, 184 (10) :1236-1245
[4]   Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC) [J].
Das, K ;
Xiong, XF ;
Yang, HL ;
Westland, CE ;
Gibbs, CS ;
Sarafianos, SG ;
Arnold, E .
JOURNAL OF VIROLOGY, 2001, 75 (10) :4771-4779
[5]   Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection [J].
de Man, RA ;
Wolters, LMM ;
Nevens, F ;
Chua, D ;
Sherman, M ;
Lai, CL ;
Gadano, A ;
Lee, Y ;
Mazzotta, F ;
Thomas, N ;
DeHertogh, D .
HEPATOLOGY, 2001, 34 (03) :578-582
[6]   Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus [J].
Delaney, WE ;
Edwards, R ;
Colledge, D ;
Shaw, T ;
Torresi, J ;
Miller, TG ;
Isom, HC ;
Bock, CT ;
Manns, MP ;
Trautwein, C ;
Locarnini, S .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (06) :1705-1713
[7]   Hepatitis B virus replication in human HepG2 cells mediated by hepatitis B virus recombinant Baculovirus [J].
Delaney, WE ;
Isom, HC .
HEPATOLOGY, 1998, 28 (04) :1134-1146
[8]   Lamivudine as initial treatment for chronic hepatitis B in the United States [J].
Dienstag, JL ;
Schiff, ER ;
Wright, TL ;
Perrillo, RP ;
Hann, HWL ;
Goodman, Z ;
Crowther, L ;
Condreay, LD ;
Woessner, M ;
Rubin, M ;
Brown, NA .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (17) :1256-1263
[9]   DIRECT LINEAR PLOT - NEW GRAPHICAL PROCEDURE FOR ESTIMATING ENZYME KINETIC-PARAMETERS [J].
EISENTHAL, R ;
CORNISH-BOWDEN, A .
BIOCHEMICAL JOURNAL, 1974, 139 (03) :715-720
[10]   SELECTIVITY OF ACTION OF AN ANTI-HERPETIC AGENT, 9-(2-HYDROXYETHOXYMETHYL)GUANINE [J].
ELION, GB ;
FURMAN, PA ;
FYFE, JA ;
DEMIRANDA, P ;
BEAUCHAMP, L ;
SCHAEFFER, HJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1977, 74 (12) :5716-5720